Literature DB >> 12214159

Effects of aspirin and clopidogrel versus oral anticoagulation on platelet function and on coagulation in patients with nonvalvular atrial fibrillation (CLAFIB).

Iris Müller1, Steffen Massberg, Wolfgang Zierhut, Christiane Binz, Alexander Schuster, Silja Rüdiger-von Hoch, Siegmund Braun, Meinrad Gawaz.   

Abstract

The aim of the study was to evaluate the effect of two antithrombotic therapies on platelet function and on coagulation in patients with nonvalvular atrial fibrillation (NVAF). Twenty patients with NVAF were treated with aspirin (300 mg/day) and clopidogrel (75 mg/day) for 2 weeks immediately followed by oral anticoagulation (target international normalized ratio 2.0-3.0). Parameters of platelet function and coagulation were evaluated before antithrombotic therapy, at the end of aspirin plus clopidogrel and during subsequent anticoagulation treatment. Aspirin plus clopidogrel significantly inhibited platelet aggregation, fibrinogen receptor activation and release of P-selectin and prolonged in vitro bleeding time (p < 0.01). Coagulation parameters (platelet-dependent thrombin generation, antithrombin III, thrombin-antithrombin III complex, prothrombin fragment 1 + 2) were not significantly affected. During the subsequent oral anticoagulation phase platelet function was not substantially reduced; however, coagulation parameters were significantly inhibited (p < 0.001). The results indicate that combined antiplatelet therapy is superior to aspirin monotherapy in inhibiting platelet function but does not seem to substantially modulate coagulation cascade in patients with NVAF. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12214159     DOI: 10.1159/000057284

Source DB:  PubMed          Journal:  Pathophysiol Haemost Thromb        ISSN: 1424-8832


  9 in total

Review 1.  Stroke and Death Prediction with the Impact of Vascular Disease in Patients with Atrial Fibrillation.

Authors:  Abhishek Maan; Amir Y Shaikh; Moussa Mansour; Jeremy N Ruskin; E Kevin Heist
Journal:  J Atr Fibrillation       Date:  2012-06-15

Review 2.  Antiplatelet therapy for stroke prevention in atrial fibrillation.

Authors:  Nadish Garg; Arun Kumar; Greg C Flaker
Journal:  Mo Med       Date:  2010 Jan-Feb

Review 3.  Stroke in atrial fibrillation--hope on the horizon?

Authors:  Shahnaz Jamil-Copley; Prapa Kanagaratnam
Journal:  J R Soc Interface       Date:  2010-09-29       Impact factor: 4.118

Review 4.  Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

Review 5.  The selection of antithrombotic agents in the prevention of recurrent ischemic stroke.

Authors:  Cathy M Helgason
Journal:  Curr Cardiol Rep       Date:  2003-03       Impact factor: 2.931

Review 6.  Fruitflow®: the first European Food Safety Authority-approved natural cardio-protective functional ingredient.

Authors:  Niamh O'Kennedy; Daniel Raederstorff; Asim K Duttaroy
Journal:  Eur J Nutr       Date:  2016-07-07       Impact factor: 5.614

7.  Thrombin-anti-thrombin levels and patency of arterio-venous fistula in patients undergoing haemodialysis compared to healthy volunteers: a prospective analysis.

Authors:  James A Milburn; Isobel Ford; Nicola J Mutch; Nicholas Fluck; Julie Brittenden
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

8.  Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials).

Authors:  Amadea M Martischnig; Julinda Mehilli; Janina Pollak; Tobias Petzold; Anette K Fiedler; Katharina Mayer; Stefanie Schulz-Schüpke; Dirk Sibbing; Steffen Massberg; Adnan Kastrati; Nikolaus Sarafoff
Journal:  Biomed Res Int       Date:  2015-07-01       Impact factor: 3.411

9.  Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension.

Authors:  Aleksandra Gąsecka; Marta Banaszkiewicz; Rienk Nieuwland; Edwin van der Pol; Najat Hajji; Hubert Mutwil; Sylwester Rogula; Wiktoria Rutkowska; Kinga Pluta; Ceren Eyileten; Marek Postuła; Szymon Darocha; Zenon Huczek; Grzegorz Opolski; Krzysztof J Filipiak; Adam Torbicki; Marcin Kurzyna
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.